Knuff & Co LLC Acquires Shares of 7,033 Thermo Fisher Scientific Inc. $TMO

Key Points

• Knuff & Co LLC acquired 7,033 Thermo Fisher Scientific shares worth approximately $3.53 million in the second quarter. Institutional investors collectively own 89.23% of TMO.
• Analysts maintain a positive outlook, with a consensus “Moderate Buy” rating and an average price target of $619.41; several firms recently raised their targets to $650.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, with year-over-year revenue growth of 10.5%. The company also declared a quarterly dividend of $0.47 per share.

Knuff & Co LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 7,033 shares of the medical research company's stock, valued at approximately $3,526,000.

Other hedge funds have also bought and sold shares of the company. NewEdge Wealth LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at $5,363,000. Flossbach Von Storch SE bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $955,580,000. Empirical Asset Management LLC purchased a new stake in Thermo Fisher Scientific during the second quarter worth about $466,000. Chancellor Financial Group WB LP bought a new stake in Thermo Fisher Scientific in the second quarter worth about $392,000. Finally, Great Lakes Advisors LLC purchased a new position in Thermo Fisher Scientific in the second quarter valued at about $5,644,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research reports. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Barclays raised their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Royal Bank Of Canada upped their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Finally, Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $614.32 on Thursday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock has a market capitalization of $227.14 billion, a price-to-earnings ratio of 33.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The stock's 50-day simple moving average is $536.26 and its 200 day simple moving average is $508.51.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company's revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is 10.11%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the sale, the chief executive officer owned 123,925 shares of the company's stock, valued at $71,191,194.75. This trade represents a 7.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president directly owned 14,784 shares of the company's stock, valued at $8,574,720. The trade was a 28.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source